Name: Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: Care management intervention strategies
Published: 2026-09-27T12:28:00-04:00

Product information and disease description Place of product in therapy Approaches to treatment

Care management intervention strategies

5 evidence topics · 4 sources

Pregnancy testing and contraception

“Verify that females of reproductive potential are not pregnant prior to initiating ATEBRIOZ” (opens the prescribing information at this quote)
“Advise females of reproductive potential to use effective contraception during treatment with ATEBRIOZ and for one week after the final dose.” (opens the prescribing information at this quote)
“Because of the potential for serious adverse reactions, including effects on bone development, in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with ATEBRIOZ and for at least one week after the final dose.” (opens the prescribing information at this quote)

Medication and food interaction review

“CYP3A4 Inhibitors: Reduce ATEBRIOZ dosage to 50 mg orally once daily when used concomitantly with a strong CYP3A4 inhibitor.” (opens the prescribing information at this quote)
“CYP3A4 Inducers: Avoid concomitant use of ATEBRIOZ with strong or moderate CYP3A4 inducers.” (opens the prescribing information at this quote)
“MATE1 and MATE2-K Substrates: Avoid concomitant use of ATEBRIOZ with MATE1 and MATE2-K substrates (e.g., metformin).” (opens the prescribing information at this quote)
“Do not administer ATEBRIOZ with grapefruit, pomelo, or juices containing these fruits.” (opens the prescribing information at this quote)

Manufacturer patient support program

“MAP provides insurance coverage and access support, financial assistance for eligible patients, personalized patient support and educational resources for patients and caregivers.” (opens the source at this quote in a new tab)

Coordination with FOP specialists and clinical trial investigators

“Each patient should have a primary physician who is willing to consult with an FOP expert and help coordinate a local care team.” (opens the source at this quote in a new tab)
“Ask if patient is enrolled in any FOP Clinical Trials and communicate with principal investigator and regional FOP specialist.” (opens the source at this quote in a new tab)

Prescriber education and growth monitoring for palovarotene

“Sohonos Educational Program and must be completed by any healthcare professional who wants to prescribe Sohonos.” (opens the source at this quote in a new tab)

“Prior to starting treatment with SOHONOS, all growing pediatric patients should undergo baseline assessment of skeletal maturity via hand/wrist and knee x-rays, standard growth curves and pubertal staging.” (opens the source at this quote in a new tab)